Dr. Stacy Moulder completed her fellowship in Hematology/Oncology at the Vanderbilt-Ingram Cancer Center, where she also obtained a Masters of Science in Clinical Investigation. She is a medical oncologist who exclusively sees breast cancer patients and has been appointed within the Breast Medical Oncology program for 10 years at MD Anderson Cancer Center, most recently as the Chief of the Section of Clinical Research. Through this appointment, she maintains a research interest in drug development with novel targeted therapies for the treatment of triple negative breast cancer, predominately as targeted therapy trials for the treatment of metastatic breast cancer or neoadjuvant trials in patients with localized, chemotherapy insensitive disease. Her research interests are focused on the mesenchymal subtype of TNBC, which includes metaplastic breast cancer, a particularly aggressive, chemotherapy refractory form of TNBC that has a high frequency of aberrations in PI3K/Akt/mTOR pathway and has demonstrated response to mTOR inhibition in combination with chemotherapy.
